These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27609503)

  • 21. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid Receptor Antagonists and Clinical Outcomes in Primary Aldosteronism: As Good as Surgery?
    Sechi LA; Colussi GL; Novello M; Uzzau A; Catena C
    Horm Metab Res; 2015 Dec; 47(13):1000-6. PubMed ID: 26667803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
    Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
    Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistant hypertension and hyperaldosteronism.
    Gonzaga CC; Calhoun DA
    Curr Hypertens Rep; 2008 Dec; 10(6):496-503. PubMed ID: 18959838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldosterone and refractory hypertension.
    Nyirenda MJ; Padfield PL
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):213-8. PubMed ID: 17940442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [PATHOPHYSIOLOGY AND CLINICAL ASPECTS OF SECONDARY ALDOSTERONISM AND ITS TREATMENT].
    HOFFMEISTER W
    Folia Clin Int (Barc); 1964 Mar; 14():124-44. PubMed ID: 14153959
    [No Abstract]   [Full Text] [Related]  

  • 29. Primary aldosteronism in hypertensive patients: clinical implications and target therapy.
    Papanastasiou L; Markou A; Pappa T; Gouli A; Tsounas P; Fountoulakis S; Kounadi T; Tsiama V; Dasou A; Gryparis A; Samara C; Zografos G; Kaltsas G; Chrousos G; Piaditis G
    Eur J Clin Invest; 2014 Aug; 44(8):697-706. PubMed ID: 24909545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of aldosterone antagonists in resistant hypertension.
    Calhoun DA
    Prog Cardiovasc Dis; 2006; 48(6):387-96. PubMed ID: 16714158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of aldosterone levels by -344 C/T CYP11B2 polymorphism and spironolactone use in resistant hypertension.
    Fontana V; de Faria AP; Barbaro NR; Sabbatini AR; Modolo R; Lacchini R; Moreno H
    J Am Soc Hypertens; 2014 Mar; 8(3):146-51. PubMed ID: 24388430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension.
    Ardhanari S; Kannuswamy R; Chaudhary K; Lockette W; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):185-95. PubMed ID: 25908467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone and volume management in hypertensive heart disease.
    Sica DA
    Semin Nephrol; 2014 May; 34(3):323-32. PubMed ID: 25016402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone prevents Na+/H+ exchange enhancement in primary aldosteronism.
    Koren W; Koldanov R; Postnov IY; Postnov YV
    Am J Hypertens; 1997 Mar; 10(3):341-5. PubMed ID: 9056693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update in primary aldosteronism.
    Stowasser M
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3623-30. PubMed ID: 19737921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aldosterone antagonists--first choice in resistant hypertension].
    Holzgreve H
    MMW Fortschr Med; 2016 Apr; 158(7):65-6. PubMed ID: 27071591
    [No Abstract]   [Full Text] [Related]  

  • 39. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms and treatment of resistant hypertension.
    Pimenta E; Gaddam KK; Oparil S
    J Clin Hypertens (Greenwich); 2008 Mar; 10(3):239-44. PubMed ID: 18326968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.